ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: LSCs exhibit aberrant activation of β-catenin in blastic phase (BP) CML patients, and β-catenin deletion leads to a profound reduction in the ability to develop BCR-ABL-induced CML in mice in vivo [74,75,76].